Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer

ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the Acclaim-3 clinical trial in the fourth quarter of 2023 AUSTIN, Texas, Aug. 10, 2023 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene…